Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FeRx targets MCT (Magnetic Targeted Carrier) method at GI (gastrointestinal) diseases:

This article was originally published in Clinica

Executive Summary

Preclinical results have suggested that FeRx' magnetic field-based drug delivery technique is a feasible method for delivering compounds to the gastrointestinal (GI) tract, the San Diego, California firm has reported. The Magnetic Targeted Carrier (MTC) technique may help treat GI diseases, such as inflammatory bowl disease and cancerous tumours of the oesophagus, stomach and colon, via an intra-luminal route of administration. FeRx has previously demonstrated delivery of MTCs via intra-arterial and intra-vesical routes of administration, possibly leading to the treatment of a variety of solid tumours, including those of the liver and bladder (see Clinica No 1004, p 24).

You may also be interested in...

Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says

Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.

Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions

Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.

ATAI Raises $125m Series C To Expand The Boundaries In Mental Health

The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts